IP Library › Granted Patent US 12,233,133
Granted Patent B2
US 12,233,133 · App. 18/517,529 · Granted Feb 25, 2025

Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery

Inventors: Thorsteinn Loftsson (Reykjavik, IS); Zoltán Fülöp (Budapest, HU)
Assignee: Oculis Operations Sàrl
A61K47/6951A61K9/0048A61K9/08A61K9/10A61K9/146A61K9/50A61K9/51A61K31/4184A61K31/573A61K47/02A61K47/10A61K47/12A61K47/186A61K47/34A61K47/38A61P27/02A61K47/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,233,133
App. No.
18/517,529
Granted
Feb 25, 2025
Kind
B2
Abstract

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.

Claims (74)

1. A topical ophthalmic microsuspension comprising in an ophthalmically acceptable medium:

a solid complex comprising dexamethasone and cyclodextrin,

wherein the cyclodextrin consists of γ-cyclodextrin which is the only cyclodextrin in the microsuspension;

wherein the dexamethasone is the only active agent and is present in the microsuspension at a concentration of about 1% to about 2% by weight based on the volume of the microsuspension (w/v); and

wherein the γ-cyclodextrin is present at a concentration of about 5% to about 20% (w/v);

wherein the solid complex has a diameter D50 from about 1 μm to about 10 μm; and,

wherein the microsuspension comprises a mixture of dexamethasone enol aldehydes at a concentration of less than 0.5% by weight based on the weight of the dexamethasone, wherein the dexamethasone enol aldehydes have the structures:

wherein the topical ophthalmic microsuspension is obtained by heating to dissolution dexamethasone in an ophthalmically acceptable medium separately from γ-cyclodextrin in a second ophthalmically acceptable medium, cooling and then combining the dexamethasone solution and the γ-cyclodextrin solution to provide the topical ophthalmic microsuspension.

2. The topical ophthalmic microsuspension of claim 1 , wherein the concentration of γ-cyclodextrin is 12% to 16% (w/v).

3. The topical ophthalmic microsuspension of claim 1 , wherein the microsuspension comprises less than 0.3% by weight of the mixture of dexamethasone enol aldehydes based on the weight of dexamethasone.

4. The topical ophthalmic microsuspension of claim 1 , wherein 60% to 95% by weight of the dexamethasone in the microsuspension is in the form of the solid complex.

5. The topical ophthalmic microsuspension of claim 1 , wherein the microsuspension further comprises a polymer.

6. The topical ophthalmic microsuspension of claim 5 , wherein the concentration of the polymer is 1% to 4% (w/v).

7. The topical ophthalmic microsuspension of claim 6 , wherein the polymer is a poloxamer.

8. The topical ophthalmic microsuspension of claim 7 , wherein the polymer is poloxamer 407.

9. The topical ophthalmic microsuspension of claim 6 , wherein the microsuspension comprises:

about 12% to about 16% (w/v) of natural γ-cyclodextrin;

about 2.2% to about 2.8% (w/v) of a polymer;

0% to about 0.2% (w/v) of a stabilizing agent which is disodium edetate;

0% to about 1% (w/v) of an electrolyte; and,

water.

10. The topical ophthalmic microsuspension of claim 9 , wherein the polymer is a poloxamer.

11. The topical ophthalmic microsuspension of claim 10 , wherein the polymer is poloxamer 407.

12. The topical ophthalmic microsuspension of claim 1 ,

wherein the microsuspension comprises:

about 1.5% (w/v) of dexamethasone;

about 14% (w/v) of γ-cyclodextrin;

about 2.5% (w/v) of a poloxamer;

about 0.08 to 0.2% (w/v) of disodium edetate as a stabilizing agent;

an electrolyte; and,

water.

13. The topical ophthalmic microsuspension of claim 12 , wherein the poloxamer is poloxamer 407.

14. The topical ophthalmic microsuspension of claim 1 , wherein the solid complex has a diameter D50 from about 3 μm to about 8 μm.

15. The topical ophthalmic microsuspension of claim 12 , wherein the electrolyte is sodium chloride.

16. The topical ophthalmic microsuspension of claim 15 , wherein the microsuspension comprises about 0.57% (w/v) sodium chloride.

17. The topical ophthalmic microsuspension of claim 1 , wherein the microsuspension has a pH between about 5.0 and about 6.0.

18. The topical ophthalmic microsuspension of claim 5 , wherein the microsuspension has a viscosity from about 4 cP to about 14 cP when measured at 25° C.

19. A topical ophthalmic microsuspension comprising, in an ophthalmically acceptable medium:

a solid complex comprising dexamethasone and cyclodextrin,

wherein the cyclodextrin consists of γ-cyclodextrin which is the only cyclodextrin in the microsuspension;

wherein the dexamethasone is the only active agent and is present in the microsuspension at a concentration of about 1% to about 2% by weight based on the volume of the microsuspension (w/v);

and wherein the γ-cyclodextrin is present in the microsuspension at a concentration of about 12% to about 16% (w/v);

about 2.2% to about 2.8% (w/v) of a polymer;

0% to about 0.2% (w/v) of disodium edetate;

0% to about 1% (w/v) of an electrolyte; and,

water;

wherein the solid complex has a diameter D50 from about 1 μm to about 10 μm;

wherein the microsuspension comprises about 70% to about 99% by weight of the dexamethasone in microparticles;

wherein the microsuspension has a viscosity from about 4 cP to about 14 cP when measured at 25° C.; and,

wherein the microsuspension comprises a mixture of dexamethasone enol aldehydes at a concentration of less than 0.5% by weight based on the weight of the dexamethasone, wherein the dexamethasone enol aldehydes have the structures:

wherein the topical ophthalmic microsuspension is obtained by heating to dissolution dexamethasone in an ophthalmically acceptable medium separately from γ-cyclodextrin in a second ophthalmically acceptable medium, cooling and then combining the dexamethasone solution and the γ-cyclodextrin solution to provide the topical ophthalmic microsuspension.

20. The topical ophthalmic microsuspension of claim 19 , wherein the concentration of γ-cyclodextrin is about 14% (w/v).

21. The topical ophthalmic microsuspension of claim 19 , wherein the concentration of dexamethasone is about 1.5% (w/v).

22. The topical ophthalmic microsuspension of claim 19 , wherein the microsuspension comprises less than about 0.3% by weight of the mixture of dexamethasone enol aldehydes based on the weight of dexamethasone.

23. The topical ophthalmic microsuspension of claim 19 , wherein the microsuspension has a pH between about 5.0 and about 6.0.

24. The topical ophthalmic microsuspension of claim 19 , wherein the ophthalmic microsuspension comprises about 0.1% of disodium edetate.

25. The topical ophthalmic microsuspension of claim 19 , wherein the electrolyte is sodium chloride.

26. The topical ophthalmic microsuspension of claim 25 , wherein the microsuspension comprises about 0.57% (w/v) sodium chloride.

27. A topical ophthalmic microsuspension comprising, in an ophthalmically acceptable medium:

a solid complex comprising dexamethasone and cyclodextrin,

wherein the cyclodextrin consists of γ-cyclodextrin and is the only cyclodextrin in the microsuspension;

wherein the dexamethasone is the only active agent and is present in the microsuspension at a concentration of about 1.5% by weight based on the volume of the microsuspension (w/v); and,

wherein the γ-cyclodextrin is present in the microsuspension at a concentration of about 14% (w/v);

about 2.5% (w/v) of poloxamer 407;

about 0.1% (w/v) of disodium edetate;

an electrolyte; and,

water;

wherein the solid complex has a diameter D50 from about 1 μm to about 10 μm;

wherein 60% to 95% by weight of the dexamethasone in the microsuspension is the form of a solid complex of dexamethasone and γ-cyclodextrin;

wherein the microsuspension has a viscosity from about 4 cP to about 14 cP when measured at 25° C.; and,

wherein the microsuspension comprises a mixture of dexamethasone enol aldehydes at a concentration of less than 0.5% by weight based on the weight of the dexamethasone, wherein the dexamethasone enol aldehydes have the structures:

wherein the topical ophthalmic microsuspension is obtained by heating to dissolution dexamethasone in an ophthalmically acceptable medium separately from γ-cyclodextrin in a second ophthalmically acceptable medium, cooling and then combining the dexamethasone solution and the γ-cyclodextrin solution to provide the topical ophthalmic microsuspension.

28. The topical ophthalmic microsuspension of claim 27 , wherein the microsuspension comprises less than about 0.3% by weight of the mixture of dexamethasone enol aldehydes based on the weight of dexamethasone.

29. The topical ophthalmic microsuspension of claim 27 , wherein the microsuspension has a pH between about 5.0 and about 6.0.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2025
From: OCULIS EHF
To: OCULIS SA
Reel/Frame 069966/0276 →
MERGER Recorded Jan 22, 2025
From: OCULIS SA
To: OCULIS OPERATIONS GMBH
Reel/Frame 069966/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2025
From: LOFTSSON, THORSTEINN; FÜLÖP, ZOLTÁN
To: OCULIS EHF
Reel/Frame 069989/0588 →
CHANGE OF NAME Recorded Jan 22, 2025
From: OCULIS OPERATIONS GMBH
To: OCULIS OPERATIONS SÀRL
Reel/Frame 070328/0684 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2024
From: KREOS CAPITAL VII (UK) LIMITED
To: OCULIS OPERATIONS SÀRL
Reel/Frame 069604/0055 →
SECURITY INTEREST Recorded Aug 19, 2024
From: OCULIS OPERATIONS SÀRL
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 068323/0768 →
Continuity (5)
Continuation 17955064 · Sep 28, 2022
Continuation 17487354 · Sep 28, 2021
Continuation 15826247 · Nov 29, 2017
Provisional Application 62427737 · Nov 29, 2016
Related Publication 20240091377A1 · Mar 21, 2024
References Cited (172)
US 5051402A · Kurihara et al. · 1991 [cited by applicant]
US 5472954A · Loftsson et al. · 1995 [cited by applicant]
US 5951971A · Kawashima et al. · 1999 [cited by applicant]
US 7893040B2 · Loftsson et al. · 2011 [cited by applicant]
US 8633172B2 · Loftsson et al. · 2014 [cited by applicant]
US 8999953B2 · Loftsson et al. · 2015 [cited by applicant]
US 10159746B2 · Lewis et al. · 2018 [cited by applicant]
US 11135311B2 · Loftsson · 2021 [cited by examiner]
US 11491240B2 · Loftsson · 2022 [cited by examiner]
US 20020045601A1 · Kawashima et al. · 2002 [cited by applicant]
US 20020064524A1 · Ceve · 2002 [cited by applicant]
US 20020198174A1 · Lyons · 2002 [cited by applicant]
US 20030059470A1 · Muller · 2003 [cited by applicant]
US 20040077562A1 · Chandavarkar · 2004 [cited by examiner]
US 20050031697A1 · Vehige et al. · 2005 [cited by applicant]
US 20050234018A1 · Lyons et al. · 2005 [cited by applicant]
US 20070020336A1 · Loftsson · 2007 [cited by examiner]
US 20070148192A1 · Laddha · 2007 [cited by examiner]
US 20080119448A1 · Friedlaender et al. · 2008 [cited by applicant]
US 20080145430A1 · Panmai et al. · 2008 [cited by applicant]
US 20090312724A1 · Pipkin et al. · 2009 [cited by applicant]
US 20130296446A1 · Furumiya et al. · 2013 [cited by applicant]
US 20140057854A1 · Mitra · 2014 [cited by examiner]
US 20140163080A1 · Horn · 2014 [cited by examiner]
US 20150071971A1 · Amancha et al. · 2015 [cited by applicant]
US 20150111838A1 · Lewis et al. · 2015 [cited by applicant]
US 20160346347A1 · Loftsson · 2016 [cited by applicant]
US 20180147214A1 · Ostrow et al. · 2018 [cited by applicant]
US 20180147297A1 · Loftsson et al. · 2018 [cited by applicant]
US 20190070198A1 · El-Shabrawi · 2019 [cited by applicant]
US 20190105264A1 · Higuchi et al. · 2019 [cited by applicant]
US 20190231782A1 · Chen et al. · 2019 [cited by applicant]
CN 1559413A · 2005 [cited by applicant]
CN 1785192A · 2006 [cited by applicant]
CN 101926760A · 2010 [cited by applicant]
CN 115837027A · 2023 [cited by applicant]
EP 0579435B1 · 1994 [cited by applicant]
EP 0709099A2 · 1996 [cited by applicant]
EP 1047406B1 · 2003 [cited by applicant]
KR 20140026953A · 2014 [cited by applicant]
WO WO199936055A1 · 1999 [cited by applicant]
WO WO2004069280A1 · 2004 [cited by applicant]
WO WO2004087100A1 · 2004 [cited by applicant]
WO WO2005105067A2 · 2005 [cited by applicant]
WO WO2009129155A2 · 2009 [cited by applicant]
WO WO2017083799A1 · 2017 [cited by applicant]
WO WO2017196881A1 · 2017 [cited by applicant]
WO WO2018100434A1 · 2018 [cited by applicant]
WO WO2020139525A1 · 2020 [cited by applicant]
WO WO2021001366A1 · 2021 [cited by applicant]
Thorsteinn Loftsson, et al, Cyclodextrin Microparticles for Drug Delivery to the Posterior Segment of the Eye: Aqueous Dexamethasone Eye Drops, 59 J Pharm. Pharmacol. 629 (Year: 2007). [cited by examiner]
U.S. Pat. No. 7,893,040, B2, U.S. Appl. No. 11/489,466, Loftsson et al., Feb. 22, 2011, [cited by applicant]
U.S. Pat. No. 8,999,953, B2, U.S. Appl. No. 14/106,265, Loftsson et al., Apr. 7, 2015. [cited by applicant]
U.S. Pat. No. 11,135,311, B2, U.S. Appl. No. 15/826,247, Loftsson et al., Oct. 5, 2021. [cited by applicant]
U.S. Pat. No. 11,491,240, A1, U.S. Appl. No. 17/487,354, Loftsson et al., Nov. 8, 2022. [cited by applicant]
US, 2022/0354869, A1, U.S. Appl. No. 17/624,311, Loftsson et al., Nov. 10, 2022. [cited by applicant]
US, 2023/0042785, A1, U.S. Appl. No. 17/973,749, Loftsson et al., Feb. 9, 2023. [cited by applicant]
U.S. Appl. No. 18/383,987, Loftsson et al., filed Oct. 26, 2023. [cited by applicant]
U.S. Appl. No. 18/383,993, Loftsson et al., filed Oct. 26, 2023. [cited by applicant]
U.S. Appl. No. 18/383,991, Loftsson et al., filed Oct. 26, 2023. [cited by applicant]
U.S. Appl. No. 18/383,999, Loftsson et al., filed Oct. 26, 2023. [cited by applicant]
U.S. Appl. No. 18/384,000, Loftsson et al., filed Oct. 26, 2023. [cited by applicant]
2.9.31 Particle size analysis by laser light diffraction, European Pharmacopeia 9.0, pp. 349-352. [cited by applicant]
Ammar et al. “Cyclodextrins in acetazolamide eye drop formulations” Pharmazie, vol. 53, pp. 559-562, Govi-Verlag Pharmazeutischer Verkag GmbH, 1998, Eschborn, Germany. [cited by applicant]
Beeley et al. Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant Journal of biomedical materials research, vol. 74, pp. 437-444, Wiley Periodicals, Inc., USA, 2005. [cited by applicant]
Bhatia, Saurabh, “Chapter 2: Nanparticles Types, classification, characterization, fabrication methods and drug delivery applications” Natural Polymer Drug Delivery Systems, pp. 33-93, 2016. [cited by applicant]
Bonini, M. et al. Self-assembly of beta-cyclodextrin in water. Part 1: Cryo-TEM and dynamic and static light scattering. Langmuir 22, pp. 1478-1484, 2006. [cited by applicant]
Brewster, Marcus E. et al. “Cycolodextrins as pharmaceutical solubilizers”, Advanced Drug Delivery Reviews, vol. 59, pp. 645-666 (2007). [cited by applicant]
Chadha, Renu et al. “Kinetics of degradation of diclofenac sodium in aqueous solution determined by a calorimetric method,” Die Pharmazie, vol. 58, pp. 631-635 (2003). [cited by applicant]
Chen, Bin et al. “A comparative study of enol aldehyde formation from betamethasone, dexamethasone, beclomethasone and related compounds under acidic and alkaline conditions” Steroids, vol. 74, No. 1, pp. 30-41, 2009. [cited by applicant]
Chen, Quan et al. “A validated, stability-indicating HPLC method for the determination of dexamethasone related substances on dexamethasone-coated drug-eluting stents” Journal of Pharmaceutical and Biomedical Analysis, … [cited by applicant]
Cohen, E.M. “Dexamethasone, Analytical Profiles of Drug Substances,” vol. 2, pp. 163-197 (1973). [cited by applicant]
Conrow, Raymond E. et al. “Corticosteroid Decomposition via a Mixed Anhydride”, The Journal of Organic Chemistry, vol. 67, pp. 6835-3836 (2002). [cited by applicant]
Dalton, K. et al. Physical Properties of soft contact lens solutions, Optometry and Vision Science, vol. 85m No. 2, pp. 122-128, Feb. 2008. [cited by applicant]
Dalton, PH “Osmolality and viscosity of artificial tears” American Academy of Optometry, downloaded from <URL https://www.aaopt.org/detail/kowledge-base-article/ph-osmolality-and-viscosity-artificial-tears> on Sep. 24, … [cited by applicant]
Duan et al. “Cyclodextrin solubilization of the antibacterial agents triclosan and tricloscarban; formation of aggregates and higher-order complexes” International Journal of Pharmaceutics, vol. 297, pp. 213-222, 2005, … [cited by applicant]
Fenyvesi, E., “Approved Pharmaceutical Products Containing Cyclodextrins,” Cyclodextrin News, vol. 27, No. 2, Feb. 2013. [cited by applicant]
Frioriksdottir, Hafru “Polymer enhancement of cyclodextrin complexation in vivo and in vitro observations,” A Doctoral Thesis, 1997, pp. 6-117, University, IS. [cited by applicant]
Gan, L. et al. “Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers” Drug Discov. Today, vol. 18, pp. 290-297, 2013. [cited by applicant]
Gonzalez-Gaitano et al., “The aggregation of cyclodextrins as studied by Photon Correction Spectroscopy” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 44, pp. 101-105, Kluwer Academic Publishers, Nether… [cited by applicant]
Gudmundsdotlir, B.S. et al. “y-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man”, J. Ocul. Pharmacol. Ther., vol. 30, pp. 35-41, 2014. [cited by applicant]
He, Y. et al. “Cyclodextrin-based aggregates and characterization by microscopy” Micron, vol. 39, pp. 495-516, 2008. [cited by applicant]
Hidaka, Teturo, et al. “Studies on betamethasone: Behavior of betamethasone in acid or alkaline medium, Photolysis and Oxidation” Yakugaku Zasshi, vol. 100, No. 1, pp. 72-80 (1980). [cited by applicant]
Higuchi, T. et al. “Phase solubility techniques. Advances in Analytical Chemistry of Instrumentation” vol. 4, pp. 117-212, 1965. [cited by applicant]
Horsky, J. et al. “Inclusion complexes of proteins: interaction of cyclodextrins with peptides containing aromatic amino acids studies by competitive spectrophotometry” J. Inclusion Phenom. Mal. Recognit, Chem., vol. 18… [cited by applicant]
International Search Report and Written Opinion for PCT/EP2020/068398, dated Aug. 17, 2020, 10 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/IB20417/001659, dated May 3, 2018, 10 pages. [cited by applicant]
Jansook, Phatsawee et al. “γCD/HPγCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye droop suspension” Journal of Pharmacy & Pharmaceutical Sciences, vol. 13, No. 3, pp. 336-350, 2010. [cited by applicant]
Jansook, Phatsawee, et al. “Effect of self-aggregation of γ-cyclodextrin on drug solubilization” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 68, pp. 229-236, 2010. [cited by applicant]
Jansook, P. et al “Cyclodextrin-poloxamer aggregates as nanocarriers in eye drop formulations: dexamethasone and amphotericin B” Taylor & Francis, 2016. [cited by applicant]
Johannessen, G. et al. “Kinetics of y-cyclodextrin nanoparticle suspension eye drops in tear fluid. Acta Ophthalmologica” vol. 92, pp. 550-556, 2014. [cited by applicant]
Johannsdoltir, S. et al. “Formulations and toxicologic in vivo studies of aqueous cyclosporin an eye drops with cyclodextrin nanoparticles” In J. Pharm. vol. 529, pp. 486-490, 2017. [cited by applicant]
Johannsdoltir S. et al. “Development of a cyclodextrin-based aqueous cyclosporin a eye drop formulations” Int. J. Pharm. vol. 493, pp. 86-95, 2015. [cited by applicant]
Jonas, “Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases” Acta Ophalmologica Scandinavia, vol. 83, 99. 645-663, Munksgaard, Denmark, 2005. [cited by applicant]
Jozwiakowski, M. et al. “Aqueous solubility behavior of three cyclodexteins” Carbohydrate Research, vol. 143, pp. 51-59, 1985. [cited by applicant]
Kabat et al. “Not all tears are created equal”, Review of Optometry, vol. 142(1), 3 pages, 2005. [cited by applicant]
Kanai, A. et al. “The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops” Transplant Proc., vol. 21, pp. 3150-3152, 1989. [cited by applicant]
Kristinsson et al. “Dexamethasone-Cyclodextrin-Polymer Co-complexes in aqueous eye drops” Investigative ophthalmology & Visual science, vol. 37, No. 6 pp. 1199-1203, Lippincott-Raven Publication USA, 1996. [cited by applicant]
Kunert, K.S. et al. “Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine” Archives of Ophthalmology, vol. 120, pp. 330-337, 2002. [cited by applicant]
Kurkov, S.V. et al. “Cyclodextrins”, Int. J. Pharm. vol. 453, pp. 167-180, 2013. [cited by applicant]
Laupacis, A. et al. “Cyclosporin A: a powerful immunosuppressant” Canadian Medical Association Journal, vol. 126, pp. 1041-1046, 1982. [cited by applicant]
Lawen, A. “Biosynthesis of cyclosphorins and other natural peptidyl proyl cis/trans isomerase inhibitors” Biochimica et Biophysica Acta, vol. 1850, pp. 2111-2120, 2015. [cited by applicant]
Le Bourlais, C. et al. “Ophthalmic drug delivery systems-recent advances. Progress in Retinal and Eye Research” vol. 17, pp. 33-58, 1998. [cited by applicant]
Li, Min Various Types and Mechanisms of Degradation Reactions, Chapter 4, RSC Drug Discovery Series No. 29, Organic Chemistry of Drug Degradation, 2012. [cited by applicant]
Loftsson et al., “Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye” International Journal of Pharmaceutics, 2017. [cited by applicant]
Loftsson et al., “Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye” Acta Ophthalmologica Scandinavia, vol. 80, pp. 144-150, Munksgaard, Denmark, 2002. [cited by applicant]
Loftsson et al. “Pharmaceutical applications of cyclodextrins: basic science and product development” Journal of Pharmacy and Pharmacology, vol. 62, pp. 1607-1621, 2010. [cited by applicant]
Loftsson, T. “Self-assembled cyclodextrin nanoparticles and drug delivery” J. Incl. Phenom. Macro. vol. 80, pp. 1-7, 2014. [cited by applicant]
Loftsson et al. “Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes” J. Pharm. Pharmacol. 63, pp. 1119-1135, 2011. [cited by applicant]
Loftsson et al. “Determination of aqueous solubility by heating and equilibration: A technical note” AAPS PharmSciTech 7, article No. 4, 2006. [cited by applicant]
Loftsson et al. “Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations” Pharmazie, vol. 63, pp. 171-179, 2008. [cited by applicant]
Loftsson et al. “Cyclodextrins in drug delivery” Expert Opinion, vol. 2, Drug Delivery, pp. 335-351, Ashley Publications Ltd. London, 2005. [cited by applicant]
Loftsson, et al. “Topical dexamethasone delivery to the retina: An aqueous cyclodextrin-based microsuspension” Journal of drug delivery science and technology, 81, 2023. [cited by applicant]
Loftsson et al. “The effects of organic salts on the cyclodextrins solubilization of drugs” International Journal of Pharmaceutics, vol. 262, pp. 101-107, 2003, Netherlands. [cited by applicant]
Loftsson et al. “The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs” J. Drug Del. Sci. Tech. vol. 14, pp. 35-43, 2004 Ed. De Sante France. [cited by applicant]
Loftsson et al. “Topical drug delivery to the eye: dorzolamide” Acta Ophthalmologica vol. 90, pp. 603-608, 2012. [cited by applicant]
Loftsson et al. “Self-Association of Cyclodextrins and Cyclodextrin Complexes”, Journal of Pharmaceutical Sciences, vol. 93, No. 5, pp. 1091-1099, Wiley-Liss, Inc. and the American Pharmacists Association, USA, 2004. [cited by applicant]
Loftsson et al. “Cyclodextrins solubilization of the antibacterial agents Triclosan and Triclocarban; Effect of ionization and polymers” Journal of inclusion phenomena and macrocyclic chemistry, vol. 52, pp. 109-117, 20… [cited by applicant]
Loftsson et al. “Pharmaceutical applications of cyclodextrins. 1 Drug solubilization and stabilization” Journal of Pharmaceutical Sciences, vol. 85, pp. 1017-1025, 1996. [cited by applicant]
Loftsson et al. “Evaluation of cyclodextrin solubilization of drugs” International Journal of Pharmaceutics, vol. 302, pp. 18-28, 2005 Netherlands. [cited by applicant]
Loftsson et al. “Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits” J. Pharm. Pharmacol. vol. 46, pp. 503-504, Pharmaceutical Press England, 1994. [cited by applicant]
Loftsson et al. Cyclodextrin Microparticles for drug delivery to the posterior segment of the eye: Aqueous dexamethasone Eye Drops, vol. 59, No. 5 J. Pharm. Pharmacol. 629-635, 2007. [cited by applicant]
Loftsson et al. “Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment” Acta Ophthalmologica, 2022. [cited by applicant]
Magnusdottir et al., “Self-association and cyclodextrin solubilizations of NSAIDs” Journal of Inclusion phenomena and macrocyclic chemistry, vol. 44, pp. 213-218, Kluwer Academic Publishers, The Netherlands, 2002. [cited by applicant]
Mele et al., “Non-covalent associations of cyclomaltooligosaccharides (cyclodextrins) with trans-B-carotene in water: evidence for the formation of large aggregates by light scattering and NMR spectroscopy”, Carbohydrat… [cited by applicant]
Messner, M. et al. “Self-assembled cyclodextrin aggregates and nanoparticles” Int. J. Pharm. vol. 387, pp. 199-208, 2010. [cited by applicant]
Miyake, K. et al. Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and- noncannulated rats: Biological & Pharmaceutical Bulletin, vol. 22, pp. 66-72, 1999. [cited by applicant]
Moya-Ortega et al. “Dexamethasone eye drops containing γ-cyclodextrin-based nanogels” Int J. Pharm. 441, 507-515, 2013. [cited by applicant]
Muankaew, C et al. “Cyclodextrin-based telmisartan Ophthalmic Suspension: Formulation development for water-insoluble drugs” International Journal of Pharmaceutics, vol. 507, pp. 21-31, 2016. [cited by applicant]
Muankaew, C. et al. “Effect of y-cyclodextrin on solubilization and complexion of irbesartan: influence of pH and excipients” Int. J. Pharm. vol. 474, pp. 80-90, 2014. [cited by applicant]
Myles et al. “Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis” Advanced drug delivery reviews, vol. 57, pp. 2063-2079, 2005, Netherlands. [cited by applicant]
Non-Final Office Action issued Jan. 19, 2021, in U.S. Appl. No. 16/465,138 (17 pages). [cited by applicant]
Final Office Action issued Jun. 1, 2021, in U.S. Appl. No. 16/465,138 (20 pages). [cited by applicant]
Non-Final Office Action issued Sep. 29, 2021, in U.S. Appl. No. 16/465,138 (13 pages). [cited by applicant]
Final Office Action issued Jan. 28, 2022, in U.S. Appl. No. 16/465,138 (13 pages). [cited by applicant]
Non-Final Office Action issued Jun. 2, 2022, in U.S. Appl. No. 16/465,138 (17 pages). [cited by applicant]
Non-Final Office Action mailed on Feb. 22, 2022, in corresponding U.S. Appl. No. 17/487,354 (13 pages). [cited by applicant]
Notice of Allowance mailed on Jun. 29, 2022, in corresponding U.S. Appl. No. 17/487,354 (9 pages). [cited by applicant]
Non-Final Office Action mailed on Sep. 12, 2019, in the corresponding U.S. Appl. No. 15/826,247 (14 pages). [cited by applicant]
Final Office Action mailed on Feb. 4, 2020, in the corresponding U.S. Appl. No. 15/826,247 (11 pages). [cited by applicant]
Non-Final Office Action mailed on Sep. 15, 2020, in the corresponding U.S. Appl. No. 15/826,247 (13 pages). [cited by applicant]
Notice of Allowability mailed on Aug. 30, 2021, in the corresponding U.S. Appl. No. 15/826,247 (4 pages). [cited by applicant]
Notice of Allowability mailed on Sep. 2, 2021, in the corresponding U.S. Appl. No. 15/826,247 (5 pages). [cited by applicant]
Notice of Allowance mailed on May 27, 2021, in the corresponding U.S. Appl. No. 15/826,247 (5 pages). [cited by applicant]
Notice of Allowance mailed on Jun. 3, 2021, in the corresponding U.S. Appl. No. 15/826,247 (9 pages). [cited by applicant]
Oculis announces positive top line results from Diamond Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops, May 22, 2023. [cited by applicant]
Oculis Completes Series A Financing, Internet website https://www.businesswire.com/news/home/20160816005055/en/Oculi . . . ; accessed Aug. 1, 2023, Reykjavik, Iceland, Aug. 16, 2016. [cited by applicant]
Ohira, Akihiro et al. “Topical dexamethasone c-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema” Acta Ophthalmologica, 93:610-615; 2015. [cited by applicant]
Peel, M. et al. “Semi-synthesis of cyclosphorins” Biochimica et Biophysica Acta, vol. 1850, pp. 2121-2144, 2015. [cited by applicant]
Raghava et al. “Periocular routes for retinal drug delivery”, Expert Opinion, Drug Delivery, vol. 1 pp. 99-114, Ashley Publications Ltd. 2004, England. [cited by applicant]
Rowe, Raymond C., et al. “Cyclodextrins”, Handbook of Pharmaceutical Excipients, 4 [cited by applicant]
Russo, S. et al. Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery, Eye (2007) 21, 58-64. [cited by applicant]
Sabadini, E. et al. “Solubility of cyclomaltooligosaccharides (cyclodextrins) in H2O and D2O: a comparative study” Carbohydrate Research vol. 341, No. 2, pp. 207-274, 2006. [cited by applicant]
Salminen et al. “Disposition of ophthalmic timolol in treated and untreated rabbit eyes. A multiple and single dose study” Exp. Eye Res. vol. 38, pp. 203-206, Academic Press Inc. London, 1984. [cited by applicant]
Search Report dated Sep. 11, 2020, Issued in corresponding Singapore Patent Application No. 11201904849T, 3 pages. [cited by applicant]
Spangler, M. et al. “A validated, stability-indicating method for the assay of dexamethasone in drug substance and drug product analyses, and the assay of preservatives in drug product”, Chromatographia, vol. 54, pp. 32… [cited by applicant]
Stamm, Hermann: Overview of the methods and techniques of measurement of nanoparticles Nanotrust-Possible Health Effects of Manufactured Nanomaterials, 52 pages, 2009. [cited by applicant]
Stefansson, Einar et al. Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double-masked, vehicle-controlled study, Acta Ophthalmologica, 101:22-33; 2023. [cited by applicant]
Stella, V.J. et al. Cyclodextrins Tox. Pathol. vol. 36, pp. 30-42, 2008. [cited by applicant]
Sugrue, M.F. “The pharmacology of antiglaucoma drugs”, Pharmacology & Therapeutics, vol. 43, pp. 91-138, 1989. [cited by applicant]
Tanito, M. et al. “Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema” Invest. Ophth. Vis. Sci. vol. 52, pp. 7944-7948, 2011. [cited by applicant]
Tayar, El et al. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosphorin A: evidence from partition coefficients and molecular dynamics simulations, J. Med. Chem. vol. 36, pp. 3753-3764, 1993. [cited by applicant]
Urtti, A. “Challenges and obstacles of ocular pharmacokinetics and drug delivery” Drug Del. Rev., vol. 58, pp. 1131-1135, 2006. [cited by applicant]
Usayapant A. et al. “Effect of 2-Hydroxypropyl-β-cyclodextrin on the Ocular Absorption of dexamethasone and dexamethasone acetate,” Pharmaceutical Research, vol. 8, No. 12, pp. 1495-1499, 1991. [cited by applicant]
Utine, C.A. et al. Topical Ophthalmic use of cyclosporin A. Ocular Immunology & Inflammation: vol. 18, pp. 352-361, 2010. [cited by applicant]
Yasukawa et al. “Intracular sustained drug delivery using implantable polymeric devices” Advanced drug delivery reviews, vol. 57, pp. 2033-2046, 2005 Netherlands. [cited by applicant]
Zimmer et al. “Microspheres and nanoparticles used in ocular delivery systems” Advanced Drug Delivery Reviews, vol. 16.pp. 61-73, 1995 Netherlands. [cited by applicant]
Loftsson et al. “Cyclodextrins in ophthalmic drug delivery” Advanced Drug Delivery Reviews, vol. 36, pp. 59-79, Netherlands, 1999. [cited by applicant]
Loftsson et al. “Cyclodextrin solubilization of benzodiazephines: formulation of midazolam nasal spray” International Journal of Pharmaceutics, vol. 212, pp. 29-40, Netherlands, 2001. [cited by applicant]
Oculis Holding AG—Form F-4 Registration Statement; Securities and Exchange Commission; Registration No. 333, filed Nov. 7, 2022. [cited by applicant]
Schloesser, Paul “Oculis eye drop secures another late-stage win, this time in post-cataract surgery inflammation and pain” Endpoint News https://endpts.com/oculis-eye-drop-meets-primary-endpoints-in-phiii-post-surgery-… [cited by applicant]
Shah, Tirth J. et al. “Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy” Clinical Ophthalmology, 12; 2223-2235; 2018. [cited by applicant]
Cited By (4)
US 12,383,565 US 12,397,001 US 12,397,002 US 12,521,448